HHS Peptide Compounding Policy (October 2026): The Six Peptides and Ten Conditions

On October 28, 2026, the Department of Health and Human Services said it will not take enforcement action against state-licensed pharmacies that compound six peptides: BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c.^[1][2] The cover is narrow. It applies only to 503A pharmacies filling a prescription for a named patient, only by the routes HHS lists for each peptide, only for single-ingredient products, and only until FDA finishes rulemaking. None of the six is an FDA-approved drug, and the policy does not make them one.^[1]

What HHS announced on October 28, 2026

The document is titled an enforcement discretion policy. That is a promise about what the government will not do. HHS says it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” who compounds with one of the six listed peptides, as long as every condition in the policy is met.^[1]

That protection lasts until each peptide “is addressed in a final rule as being included or not included on the 503A bulks list,” the list that lets a pharmacy compound from a raw ingredient that has no USP monograph and is not part of an approved drug.^[1] HHS also says it may revisit the policy, in whole or in part, if a safety signal or a product quality problem turns up.^[1] The policy is interim by its own terms.

NPR’s report put it plainly: the policy does not change the peptides’ legal status, but it creates a path for small compounders.^[2] Legally, they remain unapproved substances that are not on the 503A bulks list. In practice, HHS has said it will leave pharmacies alone if they follow its rules.

The six peptides and the routes each one may take

Appendix A names the six peptides. Appendix B fixes the chemical form of each and limits how it may be given.^[1] A pharmacy that makes oral TB-500 or injectable Semax is outside the policy, even though both peptides are on the list.

BPC-157 is the only one covered for injection, oral and topical use. Its oral route comes with a catch, covered in condition 8 below. HHS’s own testing appendix says injection should be the standard route for peptides “due to their low oral bioavailability.”^[1] For what is known about swallowing it, see oral BPC-157 capsules.

The ten conditions, in plain English

All ten must be met for the policy to apply. They are numbered here as HHS numbers them.^[1]

1. The peptide is on the list. Only the six in Appendix A qualify.
2. It matches HHS’s identity and route. The amino acid sequence, structure, weight and formula must match Appendix B, and so must the route.
3. The raw ingredient comes from an FDA-registered facility with a valid certificate of analysis. The certificate must show identity, purity, potency and the absence of contaminants such as endotoxins, heavy metals, microbes and impurities. Our guide to reading a peptide certificate of analysis explains what those tests mean.
4. The original maker is registered and follows manufacturing rules. The factory’s physical location must be on the certificate. A repacker or reseller in the middle must have checked the maker and its certificate.
5. The pharmacy reports. It tells FDA’s MedWatch program and the states involved what it compounded, any serious adverse events and any quality problems.^[9] The patient’s labeling must explain how to report a problem.
6. The label says “This is a compounded drug product. Not for resale.”
7. One peptide per product. No blends or stacks. HHS says a single ingredient makes it easier to tie an adverse event to a specific substance. Our article on peptide blends and stacks covers what that rules out.
8. Oral forms need proof they are absorbed. A pharmacy making an oral peptide must keep documentation that the specific formulation reaches “an adequate level of oral bioavailability in humans.”
9. The only device allowed is an FDA 510(k)-cleared syringe. Pens and other delivery devices are out. HHS says more complex devices add risk. The policy does not explain how this fits intranasal Semax, and it names no nasal spray device.
10. Everything else in federal drug law still applies. That includes sanitary conditions and a valid prescription written for an individual patient.

Conditions 3 and 4 do the most work. They are aimed at the gap between a pharmacy-grade ingredient and the powder sold online, and HHS attached a detailed testing standard listing the analytical methods it expects behind each certificate.^[1]

What the policy does not do

• It does not approve anything. HHS’s own document says compounded drugs are not FDA-approved, “which means FDA does not review their safety, effectiveness, or quality before they are marketed.”^[1] For the peptides that are approved drugs, see FDA-approved peptides.
• It does not put the six on the 503A bulks list. That still takes a final rule. FDA’s 503A bulks page, last updated May 14, 2026, did not mention the policy as of October 30.^[4]
• It does not cover 503B outsourcing facilities. The policy names only 503A. NPR reported that it does not apply to the larger outsourcing facilities.^[1][2] Those facilities can also fill orders for office stock that are not for a named patient, so this channel stays closed.^[5] The difference is explained in 503A vs 503B pharmacies.
• It does not cover research-use-only sellers. A website selling vials “for research” is neither a state-licensed pharmacy nor filling a prescription. HHS describes the policy as a way to discourage those products. See research-use-only vs compounded peptides.
• It does not cover other peptides. Ipamorelin, CJC-1295, AOD-9604, selank, thymosin alpha-1 and the rest are not in Appendix A, and the policy says nothing about them.^[1]
• It does not close the evidence gap. The policy changes who may make these peptides. It adds no trial data on whether they work. The peptide menu shows how thin the human evidence is for each.

How the six got here: Category 2, withdrawal and the July vote

All six spent two and a half years in FDA’s Category 2, the interim list of bulk substances the agency said may present significant safety risks. They were placed there in September 2023 and left on April 22, 2026, when the nominations were withdrawn.^[1][3] HHS notes that neither the placement nor the removal changed their status under section 503A.^[1] Leaving Category 2 gave pharmacies no route to compound them.

The six, along with emideltide, went before FDA’s Pharmacy Compounding Advisory Committee on July 23 and 24, 2026. The committee took up BPC-157, KPV, TB-500 and MOTS-c on the first day, and emideltide, Semax and epitalon on the second.^[6] FDA’s reviewers in its drug center (CDER) recommended against listing each of the six, and emideltide as well; the BPC-157 briefing document, for one, concluded that the balance of criteria “weighs against” it.^[1][7][10] The committee voted the other way. FDA has posted no tally, so the counts below are Healio’s.^[6][8]

FDA’s meeting page describes the committee’s advice as non-binding.^[6] HHS acted on the six peptides the committee backed and left out emideltide, the only one voted down.^[1][8]

Why HHS says it acted

HHS gives a general reason and a peptide-by-peptide one. The general reason is the gray market. The Secretary, according to the policy, decided that limited compounding will “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.”^[1]

For each peptide, Appendix B gives the same three-part justification. First, historical use is now documented and quantified. Second, new lot-specific certificates from FDA-registered facilities supply test results CDER said were missing, such as endotoxin and microbial counts. Third, HHS reads CDER’s safety concerns as theoretical. It calls the TB-500 concerns “inferential rather than observed” and the KPV conclusion “an absence of information rather than an observed signal.”^[1]

That third point is a judgment about missing data. An absence of observed harm in small or poorly documented human exposure is a different thing from evidence of safety, and the policy’s reporting condition exists because HHS expects to learn more once pharmacies start dispensing.^[1]

Who supports it and who opposes it

The compounding trade group backed the move. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, called it a “more accountable alternative” for patients now buying gray-market peptides, NPR reported. He also warned that supply will take time, because ingredient makers must meet the new requirements and pharmacies must check that they do.^[2]

Joshua Fritzler, president of a compounding company in central Florida, expects shortages. “We won’t be able to meet demand,” he told NPR, adding that his company would likely compound only one of the six at first.^[2]

Consumer groups objected. Public Citizen said Health Secretary Robert F. Kennedy Jr. appeared to act unilaterally instead of through rulemaking. Dr. Robert Steinbrook of its Health Research Group wrote that “Kennedy has undermined the FDA and threatened public health.”^[2] The Partnership for Safe Medicines had filed a citizen petition the week before, asking FDA to disregard the July committee vote. Its executive director said the decision leaves Americans “in a grey area as to whether peptides are safe or not.”^[2]

What changes for someone who wants one of these peptides

The legal route now runs through a prescriber and a 503A pharmacy. A prescriber has to write a prescription for you by name, and the product you get should be a single peptide, labeled “Not for resale,” with a reporting procedure on the label.^[1] A vial with no pharmacy name, a blend of two or three peptides, or a nasal spray of BPC-157 does not fit the policy.

Expect a lag. Pharmacies need suppliers whose certificates meet the new standard, and the people quoted by NPR expect demand to outrun supply for some time.^[2] Telehealth sellers that already list BPC-157 are compared in our BPC-157 seller rankings. Ask any of them which pharmacy fills the prescription, and whether it is a 503A pharmacy.

No dose of any of the six is approved, and the policy sets none; the prescriber decides. If you take one alongside a GLP-1 medicine, peptides alongside a GLP-1 covers what to tell your prescriber. FDA has taken action against research-chemical peptide sellers before, and its warning letters show the pattern the agency looks for.

Common questions